Johnson & Johnson vaccine: rare thromboses and a positive risk-benefit ratio, estimates the EMA

The essentials The European Medicines Agency believes that the benefit-risk balance of the Johnson & Johnson vaccine against Covid-19 is positive but makes a recommendation on side effects.

His opinion was eagerly awaited. The European Medicines Agency says the benefit-risk balance of the Johnson & Johnson vaccine against Covid-19 is positive in a statement released on Tuesday April 20th. However, she makes one important recommendation: to the very rare side effects of the vaccine, blood clots should be added. The European Medicines Agency has made a “possible link” to very rare cases of unusual blood clots associated with low blood platelets.

Several cases of thrombosis have been reported to the US health authorities, resulting in the suspension of delivery of the Johnson & Johnson vaccine in Europe and a suspension in the US on April 13. In France, the delivery of 200,000 vaccines was planned for pharmacies, doctors’ offices and nurses.

This vaccine benefits from a marketing authorization in France granted on April 12th by the High Authority of Health. The opinion of the European Medicines Agency should therefore enable the deliveries to begin.

Also read: Johnson & Johnson vaccine: 3 questions about the delayed use of American serum in Europe

A single injection

The Johnson & Johnson vaccine, which requires a single dose rather than two, is available to all French people over the age of 55.

It is the fourth vaccine to be approved in France after Pfizer, Moderna and AstraZeneca.

Back to top button